Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04411810 · ClinicalTrials.gov registry record · NA
SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 149
- Enrollment target
NCT04411810: Completed NA study, sponsored by NYU Langone Health.
NCT04411810 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 149 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04411810, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 149 participants
- Enrollment target
Study Summary
The overall goal of this research is to develop a platform that can increase patient access to expert skin cancer diagnostic services via telemedicine. This is especially important for medically underserved areas where melanoma outcomes are worse than in areas with greater access to in-person evaluations. If successful, the widespread availability of such services would be combined with public education efforts to encourage individuals with changing skin lesions to seek evaluation. With decreased travel times to high quality diagnostic services, such efforts may decrease the diagnosis of more advanced melanomas (with a concomitant increase in the diagnosis of earlier stage tumors), and potentially decrease melanoma mortality.
Primary Outcome
To compare the accuracy of skin cancer diagnoses between in-person recommendation and the telemedicine (tele) recommendation, the number of "positive" evaluations (i.e. recommended for biopsy) that were truly skin cancer plus the number of "negative" evaluations (i.e. not recommended for biopsy) that were truly non-cancerous divided by the total number of skin lesions evaluated is calculated.
Interventions
- PROCEDURE Skin biopsy
- DEVICE Nevisense 3.0
- DEVICE Dermlite Cam
- DEVICE Barco Demetra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2020-08-20 |
| Est. Completion | 2023-03-04 |
| Phase | NA |
What the finished NCT04411810 record still lists
NCT04411810 is an interventional study that assigns participants to a tested intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 4 interventions - of which Skin biopsy is the first listed.
NCT04411810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04411810 about?
NCT04411810 is a clinical study titled "SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer". The overall goal of this research is to develop a platform that can increase patient access to expert skin cancer diagnostic services via telemedicine. This is especially important for medically underserved areas where melanoma outcomes are worse than in areas with greater access to in-person evalua...
What is the current status of trial NCT04411810?
This trial is currently completed. It is a NA study. The enrollment target is 149 participants. The study started on 2020-08-20. Estimated completion is 2023-03-04.
What interventions are being tested in trial NCT04411810?
The interventions under investigation include: Skin biopsy (PROCEDURE), Nevisense 3.0 (DEVICE), Dermlite Cam (DEVICE), Barco Demetra (DEVICE).
Who is sponsoring clinical trial NCT04411810?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04411810's enrollment target sits among peer trials
149 702nd of 2000 higher than 1,299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI